Trade Fair

Unveiling the Flourishing French Life Science Ecosystem and its Prominent Innovators

In line with France 2030 investment plan, the French life science ecosystem has witnessed unprecedented growth, bolstered by strong public initiatives that provide essential funds and important infrastructure. France has become a hotspot for cutting-edge research, development, and innovation in life sciences. Several outstanding companies have emerged as part of this thriving environment, each playing a vital role across the value chain. Meet these innovative French companies at Nordic Life Science Days.

A renowned life science ecosystem supported by public policies

The life science ecosystem in France stands as an example of excellence, propelled by robust infrastructure and unwavering government support. With the backing of France 2030, a €54 billion investment plan, the country has made significant strides in healthcare. This forward-looking initiative has channeled substantial funds into the life sciences sector, nurturing an environment where innovation thrives.

Key to this success is the presence of world-class clusters, such as Paris Saclay or Medicen that serve as dynamic hubs for research, development, and collaboration. These clusters bring together academia, industry leaders, and startups, fostering an ecosystem that accelerates the transition of research into tangible healthcare solutions. The life science ecosystem also benefits from high-quality university hospitals, research centres and pharmaceutical centres.

Expertise throughout the life science value chain

French expertise in the life science sector is important throughout the value chain. For example, the French company Tebubio‘s mRNA production services facilitate research by providing optimised research grade material to enable companies to advance their research projects. With nine local offices in Europe, including one in Denmark, Tebubio provides a range of high-quality products and services.

French companies also offer from high-quality equipment. With over 30 years of experience and continuous development, JCE Biotechnology designs, manufactures and maintains customised isolators and personalised solutions for isolation technology dedicated to the pharmaceutical industry, hospitals, laboratories and research institutes. By providing isolators, JCE Biotechnology ensures the utmost safety and precision in critical medical treatments.

French companies are taking advantage of all available technologies, such as artificial intelligence (AI), to develop the best products. Quinten Health enables pharmaceutical companies to project the real-life impact of their products at the clinical development stage through AI-powered real-world disease and care simulation. By leveraging sophisticated AI algorithms, Quinten Health provides invaluable insights into pharmaceutical products’ efficacy and potential outcomes.

French companies at the forefront of new technologies

Visionary companies continue to drive innovation and progress within the French life science ecosystem, from research to innovative therapy. With its groundbreaking advancements, METHYS Dx exemplifies the innovative French ecosystem. The French company is developing innovative tests based on the detection of unique molecular signatures specific to different cancers from a simple blood test. These tests, which are rapid and ultra-sensitive, will enable dynamic monitoring of disease evolution and treatment response as close as possible to clinical reality.

Technology truly lies at the heart of French know-how. Indeed, Biosency, another French company, is transforming the monitoring of vital signs thanks to digital predictive solutions. Based on cardio-respiratory data and activity level measurements, Biosency’s technology monitors vital parameters through a single data collection tool and an easy-to-use, intuitive interface for data visualisation.

Medetia offers transformative therapeutics for rare diseases focusing on paediatric ciliopathies. The company develops innovative therapies for genetic diseases affecting kidney, retina, bone or cartilage and aims to address unmet medical needs and improve the quality of life for patients living with rare diseases.

Another example is Astraveus, which is revolutionising the field of CGT (cell & gene therapies) manufacturing with the Lakhesys™ platform, an end-to-end cell foundry that uses deep process optimisation and single-use, microfluidic bioprocessors to deliver better results with reduced inputs. By removing the need for large-scale infrastructure and reducing costs, Astraveus is seeking to transform patient access to these life-changing therapies.

Meet this innovative ecosystem at Nordic Life Science Days

Nordics investors or life science companies looking for French know-how or partnerships should not miss the Nordic Life Science Days in Copenhagen on 29 and 30 November. This exclusive event brings together the brightest minds, boldest ideas, and most promising investment prospects from across the Nordics and more. Last year, this not-to-be-missed event brought together 880 companies from 32 different countries and over 150 investors, which resulted in more than 3000 face-to-face meetings.

These visionary companies, which continue to drive innovation and progress within the French life science ecosystem, eagerly look forward to developing partnerships with the Nordics at the Nordic Life Science Days. This prestigious event presents a unique opportunity for companies to network, foster collaborations and expand their global reach. The French life science ecosystem, fueled by robust public initiatives and powered by exceptional innovators like Astraveus, Biosency, JCE Biotechnology, Medetia, Menthys Dx, Quinten Health and Tebubio, stands ready to shape the future of healthcare and make a profound impact on the well-being of people worldwide.